ISDA

Deposition Date 1999-07-21

Release Date 2000-07-21

Last Version Date 2024-11-20

Entry Detail

PDB ID:

1C1C

Keywords:

TRANSFERASE

Title:

CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH TNK-6123

Biological Source:

Source Organism:

Human immunodeficiency virus 1 (Taxon ID: 11676)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.31

R-Value Work:

0.23

R-Value Observed:

0.22

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:HIV-1 REVERSE TRANSCRIPTASE (A-CHAIN)
Gene (Uniprot):gag-pol
Chain IDs:A
Chain Length:560
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1

UniProt ID:P04585 Pfam ID:PF00078, PF06817, PF06815, PF00075

Protein Blast

Polymer Type:polypeptide(L)
Molecule:HIV-1 REVERSE TRANSCRIPTASE (B-CHAIN)
Gene (Uniprot):gag-pol
Chain IDs:B
Chain Length:440
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1

UniProt ID:P04585 Pfam ID:PF00078, PF06817, PF06815, PF00075

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
CSD	A	CYS	3-SULFINOALANINE

Ligand Molecules

612

Primary Citation

Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.

Hopkins, A.L, Ren, J, Tanaka, H, Baba, M, Okamato, M, Stuart, D.I, Stammers, D.K, Ren, J, Esnouf, R.M, Hopkins, A.L, Stuart, D.I, Stammers, D.K, Ren, J, Esnouf, R.M, Hopkins, A.L, Warren, J, Balzarini, J, Stuart, D.I, Ren, J, Esnouf, R.M, Hopkins, A.L, Jones, E.Y, Kirby, I, Keeling, J, Ross, C.K, Larder, B.A, Stuart, D.I, Stammers, D.K, Esnouf, R.M, Ren, J, Garman, E, Somers, D.O, Ross, C.K, Jones, E.Y, Stammers, D.K, Stuart, D.I, Esnouf, R.M, Ren, J, Hopkins, A.L, Ross, C.K, Jones, E.Y, Stammers, D.K, Stuart, D.I, Hopkins, A.L, Ren, J, Esnouf, R.M, Willcox, B.E, Jones, E.Y, Ross, C.K, Miyasaka, T, Walker, R.T, Tanaka, H, Stammers, D.K, Stuart, D.I, Ren, J, Esnouf, R.M, Hopkins, A.L, Ross, C.K, Jones, E.Y, Stammers, D.K, Stuart, D.I, Ren, J, Esnouf, R.M, Garman, E, Somers, D.O, Ross, C.K, Kirby, I, Keeling, J, Darby, G, Jones, E.Y, Stuart, D.I, Stammers, D.K, Esnouf, R.M, Ren, J, Ross, C.K, Jones, E.Y, Stammers, D.K, Stuart, D.I, Stammers, D.K, Somers, D.O, Ross, C.K, Kirby, I, Ray, P.H, Wilson, J.E, Norman, M, Ren, J, Esnouf, R.M, Garman, E, Jones, E.Y, Stuart, D.I.Show

J.Med.Chem. 42 4500 4505 (1999)

PMID: 10579814 DOI: 10.1021/jm990192c

Abstact

Two analogues of the nonnucleoside inhibitor of HIV-1 RT, MKC-442 (emivirine), containing different C6 substituents have been designed to be less susceptible to the commonly found drug-resistance mutation of Tyr181Cys. Compound TNK-6123 had a C6 thiocyclohexyl group designed to have more flexibility in adapting to the mutated drug-binding site. GCA-186 had additional 3',5'-dimethyl substituents aimed at forming close contacts with the conserved residue Trp229. Both compounds showed approximately 30-fold greater inhibitory effect than MKC-442 to the Tyr181Cys mutant virus as well as to the clinically important Lys103Asn virus. X-ray crystallographic structure determination of complexes with HIV-1 RT confirmed the predicted binding modes. These strategies might be used to improve the resilience of other NNRTI series against common drug-resistance mutations.

Legend

Protein

Chemical

Disease

Primary Citation of related structures